辛伐他汀联合依折麦布对急性心肌梗死患者T淋巴细胞亚群比例影响的研究  

Study on effects of Simvastatin combined with Ezetimibe on proportions of T lymphocyte subpopulations in patient with acute myocardial infarction

作　　者：魏红[1] 王敬萍[1] 柴晓红[1] 王日军[1] 杨晋静[1] 庞工力 王宁[1] 王婧[1] 

机构地区：[1]山西医科大学第一临床医学院,山西省太原市030001

出　　处：《中国心血管病研究》2015年第5期425-428,共4页Chinese Journal of Cardiovascular Research

摘　　要：目的 比较辛伐他汀联合依折麦布和单用辛伐他汀治疗对急性心肌梗死（AMI）患者外周血CD4＋CD28调节T细胞和CD4＋CD25＋FoxP3＋调节T细胞比例的影响,探讨依折麦布联合辛伐他汀在AMI治疗中的作用.方法 选择2014年4～11月在山西省心血管病医院重症监护室住院并治疗的AMI患者40例,随机分为对照组及试验组.对照组（20例）给予辛伐他汀40 mg每晚1次;试验组（20例）给予辛伐他汀40 mg每晚1次,联合依折麦布10 mg每日1次.所有患者分别于治疗前及治疗后15 d通过流式细胞仪检测外周血CD4＋CD28-T细胞及CD4＋CD25＋FoxP3＋T细胞占CD4＋T细胞比例.结果 对照组治疗前CD4＋CD28-T细胞占CD4＋T细胞百分比为（95.41±5.24）％,与治疗15 d后的（95.07±2.24）％比较未见统计学差异（P＞0.05）.试验组治疗前CD4＋CD28-T细胞占CD4＋T细胞百分比为（93.55±6.43）％,较治疗15 d后的（91.72士4.98）％下降,差异有统计学意义（P＜0.05）;对照组治疗前CD4＋CD25＋FoxP3＋T细胞占CD4＋T细胞百分比为（0.81±0.79）％,与治疗15 d的（0.86±0.86）％比较未见统计学差异（P＞0.05）.试验组治疗前CD4＋CD25＋FoxP3＋T细胞占CD4＋T细胞百分比为（0.85±0.87）％,与治疗15 d后的（0.62±0.57）％比较未见统计学差异（P＞0.05）.结论 AMI患者应用辛伐他汀联合依折麦布治疗可下调外周血CD4＋CD28-T淋巴细胞,而对CD4＋CD25＋FoxP3＋T淋巴细胞无明显影响.Objective To compare the effects of Simvastatin combined with Ezetimibe and Simvastatin alone on proportions of peripheral blood CD4＋CD28- and CD4＋CD25＋FoxP3＋ regulatory T cells in patients with acute myocardial infarction （AMI） and explore the effects of Simvastatin combined with Ezetimibe in AMI. Methods 40 AMI patients that were hospitalized and treated in the intensive care unit of Shanxi Cardiovascular Hospital from April 2014 to November 2014 were selected and divided randomly into two groups： the control group and the experimental group, patients in the control group （n=20） were given 40 mg Simvastatin once a day in the evening, while patients in the experimental group （n=20） were given 40 mg Simvastatin once a day in the evening and 10 mg Ezetimibe once a day. For all patients, proportions of peripheral blood CD4＋CD28- and CD4＋CD25＋ FoxP3＋ T cells in CD4＋ T cells were detected by flow cytometry before treatment and 15 days after treatment, re- spectively. Results There was no statistical significance （P〉0.05） regarding percentages of CD4＋CD28-T cells in CD4＋ T ceils before treatment （95.41±5.24）% and 15 days after treatment （95.07±2.24）% in the control group, while for the experimental group, the percentage of CD4＋CD28- T ceils in CD4＋ T cells 15 days after treatment （91.72±4.98）% decreased compared to that before treatment （93.55±6.43）%, with statistical significance （P〈 0.05 ）, there was no statistical significance （P〉0.05） regarding percentages of CD4＋CD25＋FoxP3＋ T cells in CD4＋ T cells before treatment（0.81±0.79）% and 15 days after treatment（0.86±0.86 ）% in the control group, and for the experimental group, there was no statistical significance （P〉0.05） regarding percentages of CD4＋CD25＋FoxP3＋ T ceils in CD4＋ T cells before treatment（0.85±0.87）% and 15 days after treatment（0.62±0.57）%. Conclusion Ap- plication of Simvastatin combined with Ezetimibe in AMI patients can down-regulate p

关 键 词：急性心肌梗死 动脉粥样硬化 CD4+CD28-调节性T细胞 CD4+CD25+FoxP3+调节性T细胞 流式细胞术 

分 类 号：R542.22[医药卫生—心血管疾病]